Apologies if this has been noted already, but The Australian's report on this includes comment from a Cantor Fitzgerald note on the ODAC questions predicting they will be adequately addressed by the company.
But analysts from Cantor Fitzgerald believed Mesoblast had sufficient data to allay the FDA’s concerns. “MESO has potency assays and experience from clinical trials to correlate this potency to measurable clinical outcomes,” the analysts said in a note to investors.“We think MESO will be able to address the concerns that were raised in the briefing materials. The topics of discussion were already anticipated by the company, and MESO has been preparing for the AdCom (advisory committee).”
https://www.theaustralian.com.au/business/companies/mesoblast-shares-plunge-after-us-fda-questions-covid19-treatment/news-story/dc53ea9b10c9de83c23b062e4572bc91
Apologies if this has been noted already, but The Australian's...
-
- There are more pages in this discussion • 306 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
-0.050(4.39%) |
Mkt cap ! $1.244B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.17 | $1.07 | $8.385M | 7.489M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8500 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 26954 | 3 |
View Market Depth
| Last trade - 16.10pm 19/06/2024 (20 minute delay) ? |
| MSB (ASX) Chart |